New-generation devices for transcatheter aortic valve implantation

Laura Gatto, Giuseppe Biondi-Zoccai, Enrico Romagnoli, Giacomo Frati, Francesco Prati, Arturo Giordano

Research output: Contribution to journalReview article

Abstract

Transcatheter aortic valve implantation (TAVI) has overcome the pioneering phase and thanks to accrued clinical evidence has become a mainstay alternative to surgical aortic valve replacement (SAVR) in patients at high risk for postoperative complications. Despite these successes, TAVI remains a Junior technology facing momentous developments in techniques and devices. Indeed, several new-generation devices for TAVI have become available in the last few years, including Acurate, Allegra, Evolut, Lotus, JenaValve, Portico, and SAPIEN3. Despite the inevitable setbacks, such as the one represented by DirectFlow, these new devices appear associated with comparative benefits, especially for minimal invasiveness, rates of permanent pacemaker implantation, and risk of residual aortic regurgitation. Indeed, no single device appears clearly better than the others, and a tailored and individualized approach should be sought in using these prostheses, taking into account operator and institutional expertise, on top of patient features. Few comparative effectiveness studies are available to date to guide decision making, and thus careful scrutiny is needed even in everyday clinical practice, especially if seeking to expand the current indications of TAVI. Further guidance will however come from long-term follow-up of completed studies and from results of ongoing trials.

Original languageEnglish
Pages (from-to)747-761
Number of pages15
JournalMinerva Cardioangiologica
Volume66
Issue number6
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Equipment and Supplies
fexofenadine
Aortic Valve Insufficiency
Aortic Valve
Surgical Instruments
Prostheses and Implants
Decision Making
Technology
Transcatheter Aortic Valve Replacement

Keywords

  • Aortic valve stenosis
  • Comparative effectiveness research
  • Transcatheter aortic valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gatto, L., Biondi-Zoccai, G., Romagnoli, E., Frati, G., Prati, F., & Giordano, A. (2018). New-generation devices for transcatheter aortic valve implantation. Minerva Cardioangiologica, 66(6), 747-761. https://doi.org/10.23736/S0026-4725.18.04707-2

New-generation devices for transcatheter aortic valve implantation. / Gatto, Laura; Biondi-Zoccai, Giuseppe; Romagnoli, Enrico; Frati, Giacomo; Prati, Francesco; Giordano, Arturo.

In: Minerva Cardioangiologica, Vol. 66, No. 6, 01.12.2018, p. 747-761.

Research output: Contribution to journalReview article

Gatto, L, Biondi-Zoccai, G, Romagnoli, E, Frati, G, Prati, F & Giordano, A 2018, 'New-generation devices for transcatheter aortic valve implantation', Minerva Cardioangiologica, vol. 66, no. 6, pp. 747-761. https://doi.org/10.23736/S0026-4725.18.04707-2
Gatto, Laura ; Biondi-Zoccai, Giuseppe ; Romagnoli, Enrico ; Frati, Giacomo ; Prati, Francesco ; Giordano, Arturo. / New-generation devices for transcatheter aortic valve implantation. In: Minerva Cardioangiologica. 2018 ; Vol. 66, No. 6. pp. 747-761.
@article{ab2a3fd95391481dbf7ae57b1f2f7acc,
title = "New-generation devices for transcatheter aortic valve implantation",
abstract = "Transcatheter aortic valve implantation (TAVI) has overcome the pioneering phase and thanks to accrued clinical evidence has become a mainstay alternative to surgical aortic valve replacement (SAVR) in patients at high risk for postoperative complications. Despite these successes, TAVI remains a Junior technology facing momentous developments in techniques and devices. Indeed, several new-generation devices for TAVI have become available in the last few years, including Acurate, Allegra, Evolut, Lotus, JenaValve, Portico, and SAPIEN3. Despite the inevitable setbacks, such as the one represented by DirectFlow, these new devices appear associated with comparative benefits, especially for minimal invasiveness, rates of permanent pacemaker implantation, and risk of residual aortic regurgitation. Indeed, no single device appears clearly better than the others, and a tailored and individualized approach should be sought in using these prostheses, taking into account operator and institutional expertise, on top of patient features. Few comparative effectiveness studies are available to date to guide decision making, and thus careful scrutiny is needed even in everyday clinical practice, especially if seeking to expand the current indications of TAVI. Further guidance will however come from long-term follow-up of completed studies and from results of ongoing trials.",
keywords = "Aortic valve stenosis, Comparative effectiveness research, Transcatheter aortic valve replacement",
author = "Laura Gatto and Giuseppe Biondi-Zoccai and Enrico Romagnoli and Giacomo Frati and Francesco Prati and Arturo Giordano",
year = "2018",
month = "12",
day = "1",
doi = "10.23736/S0026-4725.18.04707-2",
language = "English",
volume = "66",
pages = "747--761",
journal = "Minerva Cardioangiologica",
issn = "0026-4725",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - New-generation devices for transcatheter aortic valve implantation

AU - Gatto, Laura

AU - Biondi-Zoccai, Giuseppe

AU - Romagnoli, Enrico

AU - Frati, Giacomo

AU - Prati, Francesco

AU - Giordano, Arturo

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Transcatheter aortic valve implantation (TAVI) has overcome the pioneering phase and thanks to accrued clinical evidence has become a mainstay alternative to surgical aortic valve replacement (SAVR) in patients at high risk for postoperative complications. Despite these successes, TAVI remains a Junior technology facing momentous developments in techniques and devices. Indeed, several new-generation devices for TAVI have become available in the last few years, including Acurate, Allegra, Evolut, Lotus, JenaValve, Portico, and SAPIEN3. Despite the inevitable setbacks, such as the one represented by DirectFlow, these new devices appear associated with comparative benefits, especially for minimal invasiveness, rates of permanent pacemaker implantation, and risk of residual aortic regurgitation. Indeed, no single device appears clearly better than the others, and a tailored and individualized approach should be sought in using these prostheses, taking into account operator and institutional expertise, on top of patient features. Few comparative effectiveness studies are available to date to guide decision making, and thus careful scrutiny is needed even in everyday clinical practice, especially if seeking to expand the current indications of TAVI. Further guidance will however come from long-term follow-up of completed studies and from results of ongoing trials.

AB - Transcatheter aortic valve implantation (TAVI) has overcome the pioneering phase and thanks to accrued clinical evidence has become a mainstay alternative to surgical aortic valve replacement (SAVR) in patients at high risk for postoperative complications. Despite these successes, TAVI remains a Junior technology facing momentous developments in techniques and devices. Indeed, several new-generation devices for TAVI have become available in the last few years, including Acurate, Allegra, Evolut, Lotus, JenaValve, Portico, and SAPIEN3. Despite the inevitable setbacks, such as the one represented by DirectFlow, these new devices appear associated with comparative benefits, especially for minimal invasiveness, rates of permanent pacemaker implantation, and risk of residual aortic regurgitation. Indeed, no single device appears clearly better than the others, and a tailored and individualized approach should be sought in using these prostheses, taking into account operator and institutional expertise, on top of patient features. Few comparative effectiveness studies are available to date to guide decision making, and thus careful scrutiny is needed even in everyday clinical practice, especially if seeking to expand the current indications of TAVI. Further guidance will however come from long-term follow-up of completed studies and from results of ongoing trials.

KW - Aortic valve stenosis

KW - Comparative effectiveness research

KW - Transcatheter aortic valve replacement

UR - http://www.scopus.com/inward/record.url?scp=85057125212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057125212&partnerID=8YFLogxK

U2 - 10.23736/S0026-4725.18.04707-2

DO - 10.23736/S0026-4725.18.04707-2

M3 - Review article

C2 - 29687702

AN - SCOPUS:85057125212

VL - 66

SP - 747

EP - 761

JO - Minerva Cardioangiologica

JF - Minerva Cardioangiologica

SN - 0026-4725

IS - 6

ER -